- Annual report 2016 PDF English8.4Mb
- Annual report 2016 PDF Spanish8.4Mb
- Annual report 2016 PDF French8.4Mb
- Annual report 2016 PDF German8.4Mb
Transforming patients’ lives since 1983, Octapharma is dedicated to empowering more patients to go further in their life adventure.
In people with bleeding disorders, the clotting process doesn't work properly. In haemophilia A, haemophilia B and Von Willebrand disease (VWD) clotting factors Factor VIII, Factor IX or Von Willebrand factor (VWF) respectively are missing or don't work as they should.
This causes these patients to bleed for a longer time than those whose blood factor levels are normal. Most bleeding occurs internally, into the joints or muscles. Repeated bleeding without prompt treatment can damage the cartilage and the bone in a joint, leading to chronic arthritis and disability. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.
People with immune deficiencies are prone to severe infections due to a lack of naturally occurring protective antibodies (immunoglobulins). These patients need replacement of the missing immunoglobulins in order to protect them against infections and ensure they can lead a normal life.
Conditions where the immune system is out of balance are generally referred to as immune-mediated diseases, of which auto-immune diseases are a well-known subgroup. Immunotherapy treats immune diseases and deficiencies by inducing, enhancing, or suppressing an immune response through immunomodulation or immunoglobulin replacement therapy.
Patients in intensive care and emergency care often require immediate medical attention to prevent shock and quickly restore the body's natural balance − such as normal blood volume and clotting (coagulation) function.
Plasma and plasma derived products are used by emergency medicine physicians and paramedics around the world in life threatening and severe medical situations.